Genetic causes of cardiac arrest in patients with first heart attack
| ISRCTN | ISRCTN17749344 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN17749344 |
| Secondary identifying numbers | H-3-2010-133 |
- Submission date
- 03/11/2016
- Registration date
- 02/12/2016
- Last edited
- 25/09/2017
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Circulatory System
Plain English summary of protocol
Background and study aims
Sudden cardiac death (SCD) caused by ventricular fibrillation (VF) during a heart attack (cardiac arrest) is a leading cause of natural death worldwide. VF is a heart rhythm problem where the heart beats so rapidly and erratically, causing the chambers of the heart to quiver uselessly rather than pump blood around the body. Studies have shown that there is a genetic (inherited) component, indicating that sudden death of a family member is a risk factor for SCD and VF. Even though new insights and technology have become available, the nature of this remains poorly understood. Understanding the underlying genetic causes of SCD and VF would be a valuable means of being any to predict and prevent development of VF and develop new treatments. This study aims to evaluate the genetic components associated with VF in order to understand the underlying mechanisms.
Who can participate?
Adults having their first ST-elevations MI (STEMI – a type of heart attack) with and without VF within the first 12 hours.
What does the study involve?
Participants are recruited at the point of their STEMI. At this time, information about the participants and their medical history is collected by the researchers using questionnaires. If any information is missing, then the researchers have permission to contact the participants after they are discharged from hospital. While they are in hospital, a blood sample is collected to use for genetic analysis. After they are discharged, participants are followed up for five years to look for death of any cause by reviewing Danish nationwide registries and medical records.
What are the possible benefits and risks of participating?
There are no direct benefits or risks involved with participating.
Where is the study run from?
1. University Hospital of Copenhagen (Denmark)
2. Odense University Hospital (Denmark)
3. Aarhus University Hospital, Skejby (Denmark)
4. Aalborg University Hospital (Denmark)
When is the study starting and how long is it expected to run for?
July 2010 to July 2023
Who is funding the study?
1. The John and Birthe Meyer Foundation (Denmark)
2. The Novo Nordisk Foundation (Denmark)
Who is the main contact?
Dr Jacob Tfelt-Hansen
Contact information
Scientific
The Heart Centre
Department of Cardiology
University Hospital of Copenhagen
Rigshospitalet
Blegdamsvej 9
Copenhagen
2100
Denmark
Study information
| Study design | Nationwide prospective case-control study |
|---|---|
| Primary study design | Observational |
| Secondary study design | Case-control study |
| Study setting(s) | Hospital |
| Study type | Other |
| Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
| Scientific title | GEnetic causes of Ventricular Arrhythmias in patients with first STEMI (GEVAMI) study |
| Study acronym | GEVAMI |
| Study objectives | 1. Genetic factors play a significant role in ventricular fibrillation (VF) caused by first ST-elevation myocardial infarction (STEMI) 2. VF during ischemia has a multifactorial and complex nature with a familial aggregation, implicating a genetic cause. |
| Ethics approval(s) | National Committee on Health Research Ethics, 25/05/2011, protocol number: H-3-2010-133 |
| Health condition(s) or problem(s) studied | Ventricular fibrillation |
| Intervention | Participants are recruited at the point of first STEMI. Baseline demographics and previous medical history are collected by researchers by using standardized questionnaires while the participant is in hospital. If data was missing in the questionnaires, the researchers have permission to contact the patient after the discharge. In addition, medical records are collected and the comprehensive Danish nationwide registries are used to describe comorbidities and for follow up. Blood sample is collected during hospitalisation, often at the same time as participants undergo routine blood testing. This is used for future genetic analysis. Participants are followed up continuously for 5 years by reviewing Danish registries to assess for all-cause mortality. |
| Intervention type | Other |
| Primary outcome measure | Common and rare genetic variants associated with ventricular fibrillation (VF) during first ST-elevation myocardial infarction (STEMI), analysed by genome-wide association studies and next generation sequencing |
| Secondary outcome measures | All-cause mortality is measured using the Danish registries continuously for 5 years |
| Overall study start date | 03/07/2010 |
| Completion date | 03/07/2023 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Both |
| Target number of participants | 1500 cases and 1500 controls |
| Key inclusion criteria | Cases 1. First STEMI patients who experienced VF within the first 12 hours of symptoms of STEMI before PPCI 2. Age between 18 and 80 years 3. Caucasians 4. Cardiac symptoms lasting ≤12 hours 5. Acute ST-segment elevation revealed by ECG Controls: 1. First STEMI patients who did not have VF during the first 12 hours of symptoms of STEMI before PPCI 2. Age between 18 and 80 years 3. Caucasians 4. Cardiac symptoms lasting ≤12 hours 5. Acute ST-segment elevation revealed by ECG |
| Key exclusion criteria | 1. Cases and controls who developed VF during PPCI will be excluded because VF during PPCI is believed to be reperfusion induced; however, case patients with VF before PPCI who continued to have VF during PPCI can participate 2. Other exclusions included VF after PPCI 3. Congenital heart defects 4. Known structural heart disease 5. Use of class I and III antiarrhythmic drugs 6. Recent cancer 7. Major surgery or trauma within 4 weeks 8. Presentation with potassium concentration of <3 or >5 mmol/L 9. Because we also planned to identify genetic markers associated with VF, and because >90% of the Danish populations are white Danes, we excluded non-white Danes to reduce the risk of population stratification for future genetic analysis |
| Date of first enrolment | 03/07/2011 |
| Date of final enrolment | 03/07/2020 |
Locations
Countries of recruitment
- Denmark
Study participating centres
Department of Cardiology
Rigshospitalet
Blegdamsvej 9
Copenhagen
2100
Denmark
Søndre Blvd. 29
Odense
5000
Denmark
Palle Juul-Jensens Blvd. 99
Aarhus
8200
Denmark
Hobrovej 18-22
Aalborg
9100
Denmark
Sponsor information
Hospital/treatment centre
The Heart Centre
Rigshospitalet
Blegdamsvej 9
Copenhagen
2100
Denmark
"ROR" |
https://ror.org/05bpbnx46 |
|---|
Funders
Funder type
Charity
No information available
No information available
Results and Publications
| Intention to publish date | 03/07/2024 |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Data sharing statement to be made available at a later date |
| Publication and dissemination plan | Planned publication in a high-impact peer reviewed journal, around one year after your overall trial end date. |
| IPD sharing plan | The current data sharing plans for the current study are unknown and will be made available at a later date. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 05/01/2015 | Yes | No |
Editorial Notes
22/09/2017: Internal review.
09/02/2017: Internal review.
